Martin Murphy

Chief Executive Officer at Syncona Ltd.

Martin Murphy

Martin Murphy

Chief Executive Officer at Syncona Ltd.

Overview
Career Highlights

Syncona Investment Management Ltd.
Syncona Partners LLP
Syncona Ltd.

RelSci Relationships

475

Number of Boards

20

Birthday

1969

Age

52

Contact Data
Trying to get in touch with Martin Murphy? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Martin Murphy likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner of Syncona Investment Management Ltd at Syncona Ltd.

Relationship likelihood: Strong

Chief Investment Officer at Syncona Ltd.

Relationship likelihood: Strong

Former Executive Director, Chairman at Laird Ltd.

Relationship likelihood: Strong

Chief Executive Officer & Director at Achilles Therapeutics UK Ltd.

Relationship likelihood: Strong

Chief Executive Officer at Autolus Therapeutics Plc

Relationship likelihood: Strong

Chief Financial Officer at Syncona Ltd.

Relationship likelihood: Strong

Partner at Syncona Partners LLP

Relationship likelihood: Strong

Chief Strategy Officer at Microsoft Corporation

Relationship likelihood: Strong

Partner of Syncona Investment Management Ltd at Syncona Ltd.

Relationship likelihood: Strong

Co-Founder at Cambridge Epigenetix Ltd.

Relationship likelihood: Strong

Paths to Martin Murphy
Potential Connections via
Relationship Science
You
Martin Murphy
Chief Executive Officer at Syncona Ltd.
Education
Class of 1994

The University of Cambridge (informally known as Cambridge University or Cambridge) is a public research university located in Cambridge, United Kingdom. It is the second-oldest university in the English-speaking world (after the University of Oxford), and the seventh-oldest in the world.

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

Career History
Chief Executive Officer
2017 - Current

SIM uses a long-term view with a strategic capital base.

Chief Executive Officer
2012 - Current

Syncona Partners is an active manager invests early transactions. The firm in which they invests include life science innovation.

Chief Executive Officer
Current

Syncona Ltd. is a closed-end investment fund. It engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. The company operates through the following segments: Life science portfolio and Capital pool investments. The Life science portfolio segment activities focuses on developing products to deliver transformational treatments to patients. The Capital pool investments segment invests in a diversified portfolio of hedge, equity and long-term alternative investment funds across multiple asset classes. Syncona was founded on August 14, 2012 and is headquartered in St. Peter Port, the United Kingdom.

Boards & Committees
Chairman
Current

Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom.

Director
Current

Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.

Director
Prior - 2011

Healthcare Brands International (HBI) is a new company, established in the UK in October 2006, and participating primarily in the growing market of OTC Medicines. The company is committed to acquiring, developing and investing in differentiated healthcare products. In short it will translate innovative science into meaningful consumer brands.Funded with over £100 million of venture capital from leading international venture capital investors, the company is a team of experienced OTC blue chip business professionals with an unrivalled network of partners and contacts around the world (with particular strength in Europe). It brings core skills in consumer marketing and brand development and combine with partners providing in-market operational and regulatory expertise.It will focus on innovative products with meaningful and substantiated differentiation that meet a relevant and yet unmet or only partially met consumer need and thereby help grow the overall self-medication market.

Investments
Details Hidden

Desktop Genetics Ltd. develops software tools to enable literal desktop genetics. It offers technologies at the intersection of biotechnology, software and laboratory automation. The firm specializes in synthetic biology, genome engineering, genome editing, functional genomics, bioinformatics, and screening. The company was founded by Victor Dillard, Riley Doyle and Edward Perello in 2012 and is headquartered in London, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Martin Murphy. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Martin Murphy's profile does not indicate a business or promotional relationship of any kind between RelSci and Martin Murphy.